193 related articles for article (PubMed ID: 28589388)
1. [Efficacy and safety analysis of off-label treatment with biologics in autoinflammatory diseases : Experiences from a German registry (GRAID2)].
Proft F; Fleck M; Fiehn C; Schulze-Koops H; Witt M; Dörner T; Henes JC
Z Rheumatol; 2018 Feb; 77(1):46-54. PubMed ID: 28589388
[TBL] [Abstract][Full Text] [Related]
2. [Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].
Proft F; Schulze-Koops H; Grunke M; Schrezenmeier E; Halleck F; Henes J; Unger L; Schmidt E; Fiehn C; Jacobi A; Iking-Konert C; Kneitz C; Schmidt RE; Bannert B; Voll RE; Fischer-Betz R; Kötter I; Tony HP; Holle J; Aringer M; Erler A; Behrens F; Burmester GR; Dörner T
Z Rheumatol; 2018 Feb; 77(1):28-39. PubMed ID: 28589389
[TBL] [Abstract][Full Text] [Related]
3. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.
Rossi-Semerano L; Fautrel B; Wendling D; Hachulla E; Galeotti C; Semerano L; Touitou I; Koné-Paut I;
Orphanet J Rare Dis; 2015 Feb; 10():19. PubMed ID: 25758134
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
Arnold DD; Yalamanoglu A; Boyman O
Front Immunol; 2022; 13():888392. PubMed ID: 35874710
[TBL] [Abstract][Full Text] [Related]
5. [Off-label biologic therapy of ANCA-associated and non-ANCA-associated small-vessel vasculitis : Efficacy and safety analysis of a national registry (GRAID2)].
Venhoff N; Proft F; Schulze-Koops H; Holle J; Voll RE; Iking-Konert C; Jacobi AM; Henes J; Unger L; Kneitz O; Dörner T; Thiel J
Z Rheumatol; 2018 Feb; 77(1):21-27. PubMed ID: 28508096
[TBL] [Abstract][Full Text] [Related]
6. [Off-label biological therapies in patients with large vessel vasculitis and/or polymyalgia rheumatica : Safety and efficacy analysis of a nationwide German registry (GRAID2)].
Henes JC; Schulze-Koops H; Witt M; Tony HP; Mueller F; Grunke M; Czihal M; Dörner T; Proft F
Z Rheumatol; 2018 Feb; 77(1):12-20. PubMed ID: 28536934
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry.
Kuemmerle-Deschner JB; Kallinich T; Henes J; Kortus-Götze B; Oommen PT; Rech J; Krickau T; Weller-Heinemann F; Horneff G; Janda A; Foeldvari I; Schuetz C; Dressler F; Borte M; Hufnagel M; Meier F; Fiene M; Andreica I; Weber-Arden J; Blank N
RMD Open; 2024 Feb; 10(1):. PubMed ID: 38360038
[TBL] [Abstract][Full Text] [Related]
8. Targeting cytokines to treat autoinflammatory diseases.
Hausmann JS
Clin Immunol; 2019 Sep; 206():23-32. PubMed ID: 30394352
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of biologic treatments in Familial Mediterranean Fever.
Akgul O; Kilic E; Kilic G; Ozgocmen S
Am J Med Sci; 2013 Aug; 346(2):137-41. PubMed ID: 23276893
[TBL] [Abstract][Full Text] [Related]
10. IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives.
Malcova H; Strizova Z; Milota T; Striz I; Sediva A; Cebecauerova D; Horvath R
Front Immunol; 2020; 11():619257. PubMed ID: 33603750
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetic analysis for periodic fever syndromes: a supplemental role for the diagnosis of adult-onset Still's disease.
Li H; Abramova I; Chesoni S; Yao Q
Clin Rheumatol; 2018 Aug; 37(8):2021-2026. PubMed ID: 29909561
[TBL] [Abstract][Full Text] [Related]
12. International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome.
Ozen S; Kuemmerle-Deschner JB; Cimaz R; Livneh A; Quartier P; Kone-Paut I; Zeft A; Spalding S; Gul A; Hentgen V; Savic S; Foeldvari I; Frenkel J; Cantarini L; Patel D; Weiss J; Marinsek N; Degun R; Lomax KG; Lachmann HJ
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):578-586. PubMed ID: 27723279
[TBL] [Abstract][Full Text] [Related]
13. Macrophage activation syndrome complicating adult onset Still's disease: A single center case series and comparison with literature.
Lenert A; Yao Q
Semin Arthritis Rheum; 2016 Jun; 45(6):711-6. PubMed ID: 26672682
[TBL] [Abstract][Full Text] [Related]
14. State of care for patients with systemic autoinflammatory diseases - Results of a tertiary care survey.
Chuamanochan M; Weller K; Feist E; Kallinich T; Maurer M; Kümmerle-Deschner J; Krause K
World Allergy Organ J; 2019; 12(3):100019. PubMed ID: 30937142
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of biological agents in adult-onset Still's disease.
Cavalli G; Franchini S; Aiello P; Guglielmi B; Berti A; Campochiaro C; Sabbadini MG; Baldissera E; Dagna L
Scand J Rheumatol; 2015; 44(4):309-14. PubMed ID: 25656459
[TBL] [Abstract][Full Text] [Related]
16. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
17. [The most frequent febrile syndromes and autoinflammatory diseases in adulthood].
Pankow A; Krusche M
Z Rheumatol; 2024 Jun; 83(5):363-375. PubMed ID: 38802504
[TBL] [Abstract][Full Text] [Related]
18. Canakinumab as first-line biological therapy in Still's disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry.
Vitale A; Caggiano V; Maggio MC; Lopalco G; Emmi G; Sota J; La Torre F; Ruscitti P; Bartoloni E; Conti G; Fabiani C; Mattioli I; Gaggiano C; Cardinale F; Dagna L; Campochiaro C; Giacomelli R; Balistreri A; Laskari K; Tufan A; Ragab G; Almaghlouth IA; Więsik-Szewczyk E; Pereira RM; Frediani B; Iannone F; Sfikakis PP; Cantarini L
Front Med (Lausanne); 2022; 9():1071732. PubMed ID: 36619631
[TBL] [Abstract][Full Text] [Related]
19. Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based Review.
Watanabe E; Sugawara H; Yamashita T; Ishii A; Oda A; Terai C
Case Rep Med; 2016; 2016():5656320. PubMed ID: 27688774
[TBL] [Abstract][Full Text] [Related]
20. Overlap syndrome between Familial Mediterranean fever and tumor necrosis factor receptor-associated periodic syndrome in a lupus patient.
Nonaka F; Migita K; Iwasaki K; Shimizu T; Kawakami A; Yasunami M; Eguchi K
Tohoku J Exp Med; 2014 Jun; 233(2):73-7. PubMed ID: 24835548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
